PayerTalkCE Presents: Applying Real-World Experience to Better Manage the Use of Oncology Biosimilars

Learn About:

• Considerations associated with adoption of oncology biosimilars
• The use of real-world experience to address evidence gaps and reduce barriers to biosimilar utilization
• RWE payer strategies to manage the use of biosimilars in oncology care

Expert Faculty Presenters:

Raj W. Duggal, PharmD, BCOP Clinical Manager - Oncology Pharmacy Indiana University Health Click here for biography James T. Kenney, RPh, MBA Founder and President JT Kenney, LLC Click here for biography Cate Lockhart, MS, PharmD, PhD Executive Director Biologics and Biosimilars Collective Intelligence Consortium Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Real-world experience (RWE) has long been used to inform decisions about access and reimbursement policies. However, RWE strategies are not consistently applied to manage the use of biosimilars in oncology care that may improve patient access and without equivalent coverage in payer reimbursement policies, biosimilars stand at a significant access disadvantage compared to reference products and patients will struggle to gain access to these high-quality, potentially lower-cost treatment options. In many cases, utilization management data can be combined with clinical data gleaned from the EHR to provide a more robust view into the relationship between payer policies and clinical outcomes. With the ability to track patients over time, RWE can help provide managed care and payer stakeholders a more comprehensive view of patient response to biosimilars that can be used to inform future clinical decisions, as well as access, coverage, and reimbursement policies.

Educational Objectives
After completing this activity, the participant should be better able to:

• Identify key considerations associated with adoption of oncology biosimilars for the treatment of lymphoma, colorectal, lung, and breast cancer
• Discuss the use of real-world experience (RWE) including implementation, switching, and health economic data to address evidence gaps and reduce barriers to biosimilar utilization
• Apply RWE payer strategies to manage the use of biosimilars in oncology care and improve patient access to high quality care

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Impact Education, LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Medical Education Resources designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Medical Education Resources designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

UAN: JA0003680-9999-22-013-L01-P
Type of Activity: Knowledge

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources (MER) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to MER policy. MER is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

The MER planners and managers have nothing to disclose.
The Impact Education, LLC^® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.